Dr Sarah Pett

Aichelburg A; Pett SL; Cooper DA, 2002, 'AIDS as a World Health Problem', in AIDS as a World Health Problem, edn. Original, MacMillan Publishers, www.els.net, pp. 1 - 6

Kityo C; Szubert AJ; Siika A; Heyderman R; Bwakura-Dangarembizi M; Lugemwa A; Mwaringa S; Griffiths A; Nkanya I; Kabahenda S, 2018, 'Raltegravir-intensified initial antiretroviral therapy in advanced HIV disease in Africa: A randomised controlled trial', PLoS medicine, vol. 15, pp. e1002706, http://dx.doi.org/10.1371/journal.pmed.1002706

Castillo-Mancilla JR; Phillips AN; Neaton JD; Neuhaus J; Collins S; Mannheimer S; Pett S; Touzeau-Römer V; Polizzotto MN; Lundgren JD, 2018, 'Association of Suboptimal Antiretroviral Therapy Adherence with Inflammation in Virologically Suppressed Individuals Enrolled in the SMART Study', Open Forum Infectious Diseases, vol. 5, http://dx.doi.org/10.1093/ofid/ofx275

Simonsen L; Higgs E; Taylor RJ; Wentworth D; Cozzi-Lepri A; Pett S; Dwyer DE; Davey R; Lynfield R; Losso M, 2018, 'Using clinical research networks to assess severity of an emerging influenza pandemic', Clinical Infectious Diseases, vol. 67, pp. 341 - 349, http://dx.doi.org/10.1093/cid/ciy088

Mallewa J; Szubert AJ; Mugyenyi P; Chidziva E; Thomason MJ; Chepkorir P; Abongomera G; Baleeta K; Etyang A; Warambwa C, 2018, 'Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy (REALITY): an open-label, parallel-group, rand', The Lancet HIV, vol. 5, pp. e231 - e240, http://dx.doi.org/10.1016/S2352-3018(18)30038-9

Powers JH; Bacci ED; Leidy NK; Poon JL; Stringer S; Memoli MJ; Han A; Fairchok MP; Coles C; Owens J, 2018, 'Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)', PLoS ONE, vol. 13, http://dx.doi.org/10.1371/journal.pone.0194180

Post FA; Szubert AJ; Prendergast AJ; Johnston V; Lyall H; Fitzgerald F; Musiime V; Musoro G; Chepkorir P; Agutu C, 2018, 'Causes and Timing of Mortality and Morbidity among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial', Clinical Infectious Diseases, vol. 66, pp. S132 - S139, http://dx.doi.org/10.1093/cid/cix1141

Pett SL; Kunisaki KM; Wentworth D; Griffin TJ; Kalomenidis I; Nahra R; Sanchez RM; Hodgson SW; Ruxrungtham K; Dwyer D, 2018, 'Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study', Open Forum Infectious Diseases, vol. 5, http://dx.doi.org/10.1093/ofid/ofx228

Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D, 2018, 'Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study', HIV Medicine, vol. 19, pp. 65 - 71, http://dx.doi.org/10.1111/hiv.12532

Powers JH; Bacci ED; Guerrero ML; Leidy NK; Stringer S; Kim K; Memoli MJ; Han A; Fairchok MP; Chen WJ, 2018, 'Reliability, Validity, and Responsiveness of InFLUenza Patient-Reported Outcome (FLU-PRO©) Scores in Influenza-Positive Patients', Value in Health, vol. 21, pp. 210 - 218, http://dx.doi.org/10.1016/j.jval.2017.04.014

Peterson RL; Vock DM; Powers JH; Emery S; Cruz EF; Hunsberger S; Jain MK; Pett S; Neaton JD, 2017, 'Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization', Clinical Trials, vol. 14, pp. 264 - 276, http://dx.doi.org/10.1177/1740774517697919

Kelly ML; Pinto AN; Suan D; Marriott D; Cooper DA; Pett SL, 2017, 'Managing two decades of visceral leishmaniasis and HIV co-infection: A case report that illustrates the urgent research needs in the field', Sexual Health, vol. 14, pp. 286 - 288, http://dx.doi.org/10.1071/SH16036

Ryder S; Pett S; Cooke GS, 2016, 'Genotype 4 and the global challenge of hepatitis C treatment', The Lancet Gastroenterology and Hepatology, vol. 1, pp. 3 - 4, http://dx.doi.org/10.1016/S2468-1253(16)30006-1

Fox-Lewis A; Brima N; Muniina P; Grant AD; Edwards SG; Miller RF; Pett SL, 2016, 'Tuberculosis screening in patients with HIV: An audit against UK national guidelines to assess current practice and the effectiveness of an electronic tuberculosis-screening prompt', International Journal of STD and AIDS, vol. 27, pp. 901 - 905, http://dx.doi.org/10.1177/0956462416628355

Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Madero JS; Belloso W; Tu E; Silk D, 2016, 'Maraviroc, as a switch option, in HIV-1-infected individuals with stable, well-controlled HIV replication and R5-tropic virus on their first Nucleoside/Nucleotide reverse transcriptase inhibitor plus', Clinical Infectious Diseases, vol. 63, pp. 122 - 132, http://dx.doi.org/10.1093/cid/ciw207

Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD; Agan BK; Alston-Smith B, 2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, vol. 16, pp. 1 - 9, http://dx.doi.org/10.1111/hiv.12227

Murray DD; Suzuki K; Law M; Trebicka J; Neuhaus J; Wentworth D; Johnson M; Vjecha MJ; Kelleher AD; Emery S, 2015, 'Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study', PLoS ONE, vol. 10, http://dx.doi.org/10.1371/journal.pone.0139981

Amin J; Becker S; Belloso W; Boffito M; Cooper D; Crabtree-Ramirez B; Duncombe C; Foulkes S; Hill A; Jessen H, 2015, 'Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study', The Lancet Infectious Diseases, vol. 15, pp. 793 - 802, http://dx.doi.org/10.1016/S1473-3099(15)70060-5

Borges ÁH; O'Connor JL; Phillips AN; Rönsholt FF; Pett S; Vjecha MJ; French MA; Lundgren JD, 2015, 'Factors Associated with Plasma IL-6 Levels during HIV Infection', Journal of Infectious Diseases, vol. 212, pp. 585 - 595, http://dx.doi.org/10.1093/infdis/jiv123

Mocroft A; Lundgren JD; Ross M; Law M; Reiss P; Kirk O; Smith C; Wentworth D; Neuhaus J; Fux CA, 2015, 'Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study', PLoS Medicine, vol. 12, http://dx.doi.org/10.1371/journal.pmed.1001809

Madhavi V; Ana-Sosa-Batiz FE; Jegaskanda S; Center RJ; Winnall WR; Parsons MS; Ananworanich J; Cooper DA; Kelleher AD; Hsu D, 2015, 'Antibody-dependent effector functions against HIV decline in subjects receiving antiretroviral therapy', Journal of Infectious Diseases, vol. 211, pp. 529 - 538, http://dx.doi.org/10.1093/infdis/jiu486

Borges AH; O'Connor JL; Phillips AN; Rönsholt FF; Pett S; Vjecha MJ; French MA; Lundgren JD, 2014, 'Determinants of IL-6 levels during HIV infection.', J Int AIDS Soc, vol. 17, pp. 19482, http://dx.doi.org/10.7448/IAS.17.4.19482

Pinto A; Pett S; Jackson Y, 2014, 'Identifying chagas disease in Australia: An emerging challenge for general practitioners', Australian Family Physician, vol. 43, pp. 440 - 442

Seddiki N; Cook L; Hsu DC; Phetsouphanh C; Brown K; Xu Y; Kerr SJ; Cooper DA; Munier CML; Pett S, 2014, 'Human antigen-specific CD4⁺CD25⁺CD134⁺CD39⁺ T cells are enriched for regulatory T cells and comprise a substantial proportion of recall responses', European Journal of Immunology, vol. 44, pp. 1644 - 1661, http://dx.doi.org/10.1002/eji.201344102

2014, 'Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial', The Lancet, http://dx.doi.org/10.1016/S0140-6736(13)62187-X

Jackson Y; Pinto A; Pett S, 2014, 'Chagas disease in Australia and New Zealand: Risks and needs for public health interventions', Tropical Medicine and International Health, vol. 19, pp. 212 - 218, http://dx.doi.org/10.1111/tmi.12235

Phetsouphanh C; Xu Y; Bailey M; Zaunders J; Kelleher AD; Pett S; Seddiki N, 2014, 'Ratios of effector to central memory antigen-specific CD4 T cells vary with antigen exposure in HIV+ patients', Immunology and Cell Biology, http://dx.doi.org/10.1038/icb.2013.101

Babiker AG; Emery S; Fätkenheuer G; Gordin FM; Grund B; Lundgren JD; Neaton JD; Pett SL; Phillips A; Touloumi G, 2013, 'Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study', Clinical Trials, vol. 10, pp. S5 - S36, http://dx.doi.org/10.1177/1740774512440342

Hsu DC; Kerr SJ; Pett SL; Zaunders JJ; Kelleher AD; Cooper DA; Thongpaeng P; Iampornsin T; Avihingsanon A; Ubolyam S, 2013, 'Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy', Journal of Infection, http://dx.doi.org/10.1016/j.jinf.2013.11.016

Hsu DC; Kerr SJ; Iampornsin T; Pett SL; Avihingsanon A; Thongpaeng P; Zaunders JJ; Ubolyam S; Ananworanich J; Kelleher AD, 2013, 'Restoration of CMV-Specific-CD4 T Cells with ART Occurs Early and Is Greater in Those with More Advanced Immunodeficiency', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0077479

Bjerk SM; Baker JV; Emery S; Neuhaus J; Angus B; Gordin FM; Pett SL; Stephan C; Kunisaki KM, 2013, 'Biomarkers and Bacterial Pneumonia Risk in Patients with Treated HIV Infection: A Case-Control Study', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0056249

Lee FJ; Amin J; Bloch M; Pett SL; Marriott D; Carr A, 2013, 'Skeletal muscle toxicity associated with raltegravir-based combination antiretroviral therapy in HIV-infected adults', Journal of Acquired Immune Deficiency Syndromes, vol. 62, pp. 525 - 533, http://dx.doi.org/10.1097/QAI.0b013e3182832578

Davey RT; Lynfield R; Dwyer DE; Losso MH; Cozzi-Lepri A; Wentworth D; Lane HC; Dewar R; Rupert A; Metcalf JA, 2013, 'The Association between Serum Biomarkers and Disease Outcome in Influenza A(H1N1)pdm09 Virus Infection: Results of Two International Observational Cohort Studies', PLoS ONE, vol. 8, http://dx.doi.org/10.1371/journal.pone.0057121

Tu E; Swenson LC; Land S; Pett S; Emery S; Marks K; Kelleher AD; Kaye S; Kaiser R; Schuelter E, 2013, 'Results of external quality assessment for proviral DNA testing of HIV tropism in the Maraviroc switch collaborative study', Journal of Clinical Microbiology, vol. 51, pp. 2063 - 2071, http://dx.doi.org/10.1128/JCM.00510-13

Botes LP; Pett S; Carr A; Marriott D; Cooper DA; Matthews G; Carbone S; Kumaradevan N; McHugh L; Hillman RJ, 2013, 'Anal cytological abnormalities are poor predictors of high-grade intraepithelial neoplasia amongst HIV-positive men who have sex with men', Sexual Health, vol. 10, pp. 9 - 17, http://dx.doi.org/10.1071/SH11135

Boesecke C; Pett SL, 2012, 'Clinical studies with chemokine receptor-5 (CCR5)-inhibitors', Current Opinion in HIV and AIDS, vol. 7, pp. 456 - 462, http://dx.doi.org/10.1097/COH.0b013e328356e933

Carey D; Pett SL; Bloch M; Wand H; MacRae K; Beileiter K; Ray JE; Boyd MA; Emery S; Cooper DA, 2012, 'A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults', Journal of Acquired Immune Deficiency Syndromes, vol. 60, pp. 143 - 149, http://dx.doi.org/10.1097/QAI.0b013e318252f97e

Hsu DC; Zaunders JJ; Plit M; Leeman C; Ip S; Iampornsin T; Pett SL; Bailey M; Amin J; Ubolyam S, 2012, 'A novel assay detecting recall response to Mycobacterium tuberculosis: Comparison with existing assays', Tuberculosis, vol. 92, pp. 321 - 327, http://dx.doi.org/10.1016/j.tube.2012.03.008

Dwyer DE; INSIGHT Influenza Study Group, 2011, 'Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002 and FLU 003 studies.', Vaccine, vol. 29 Suppl 2, pp. B56 - B62, http://dx.doi.org/10.1016/j.vaccine.2011.04.105

Pett SL; Carey C; Lin E; Wentworth D; Lazovski J; Miró J; Gordin F; Angus B; Rodriguez-Barradas M; Rubio R, 2011, 'Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)', HIV Medicine, vol. 12, pp. 219 - 227, http://dx.doi.org/10.1111/j.1468-1293.2010.00875.x

Wallace BJ; Tan KB; Pett SL; Cooper DA; Kossard S; Whitfeld MJ, 2011, 'Enfuvirtide injection site reactions: A clinical and histopathological appraisal', Australasian Journal of Dermatology, vol. 52, pp. 19 - 26, http://dx.doi.org/10.1111/j.1440-0960.2010.00717.x

Botes LP; Jin F; Bourne C; Pett S; Marriott D; Carr A; Cooper DA; Matthews G; Brew BJ; Hillman RJ, 2011, 'Participants perspectives of self-collected anal cytological swabs', Sexual Health, vol. 8, pp. 257 - 258, http://dx.doi.org/10.1071/SH10037

Hillman RJ; Pett S; Marriott D; Carr A; Cooper DA; Matthews GV; Brew BJ; Milliken S; Botes LP, 2011, 'Participants' perspectives of high resolution anoscopy', Sexual Health, vol. 8, pp. 255 - 256, http://dx.doi.org/10.1071/SH10116

Pett SL; Emery S; Kelleher AD; Cooper DA, 2010, 'Antiretroviral agents: Focus on Maraviroc for the Treatment of HIV-1-Infected Adults', CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, vol. 2, pp. 697 - 713, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000215767200065&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pett SL; Zaunders J; Bailey M; Murray J; MacRae K; Emery S; Cooper DA; Kelleher AD, 2010, 'A novel chemokine-receptor-5 (CCR5) blocker, SCH532706, has differential effects on CCR5⁺CD4⁺ and CCR5⁺CD8⁺ T cell numbers in chronic HIV infection', AIDS Research and Human Retroviruses, vol. 26, pp. 653 - 661, http://dx.doi.org/10.1089/aid.2009.0278

Neuhaus J; Jacobs DR; Baker JV; Calmy A; Duprez D; Rosa AL; Kuller LH; Pett SL; Ristola M; Ross MJ, 2010, 'Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection', Journal of Infectious Diseases, vol. 201, pp. 1788 - 1795, http://dx.doi.org/10.1086/652749

Pett SL; Kelleher AD; Emery S, 2010, 'Role of interleukin-2 in patients with HIV infection', Drugs, vol. 70, pp. 1115 - 1130, http://dx.doi.org/10.2165/10898620-000000000-00000

Pett SL, 2009, 'Immunotherapies in HIV-1 infection', Current Opinion in HIV and AIDS, vol. 4, pp. 188 - 193, http://dx.doi.org/10.1097/COH.0b013e328329d090

Pett SL; McCarthy MC; Cooper DA; MacRae K; Tendolkar A; Norris R; Strizki JM; Williams KM; Emery S, 2009, 'A phase I study to explore the activity and safety of SCH532706, a small molecular chemokine receptor-5 antagonist in HIV type-1-infected patients', Antiviral Therapy, vol. 14, pp. 111 - 115

Seddiki N; Sasson SC; Santner-Nanan B; Munier M; van Bockel D; Ip S; Marriott D; Pett S; Nanan R; Cooper DA, 2009, 'Proliferation of weakly suppressive regulatory CD4⁺ T cells is associated with over-active CD4⁺ T-cell responses in HIV-positive patients with mycobacterial immune restoration di', European Journal of Immunology, vol. 39, pp. 391 - 403, http://dx.doi.org/10.1002/eji.200838630

Zaunders JJ; Munier ML; Seddiki N; Pett S; Ip S; Bailey M; Xu Y; Brown K; Dyer WB; Kim M, 2009, 'High levels of human antigen-specific CD4⁺ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40)', Journal of Immunology, vol. 183, pp. 2827 - 2836, http://dx.doi.org/10.4049/jimmunol.0803548

Boyd M; Pett S, 2008, 'Experimental and clinical pharmacology - HIV fusion inhibitors: a review', AUSTRALIAN PRESCRIBER, vol. 31, pp. 66 - 69, http://dx.doi.org/10.18773/austprescr.2008.040

Dyer WB; Pett SL; Sullivan JS; Emery S; Cooper DA; Kelleher AD; Lloyd A; Lewin SR, 2007, 'Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples', Clinical and Vaccine Immunology, vol. 14, pp. 52 - 59, http://dx.doi.org/10.1128/CVI.00214-06

Stark D; Pett S; Marriott D; Harkness J, 2006, 'Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient', Journal of Clinical Microbiology, vol. 44, pp. 1178 - 1180, http://dx.doi.org/10.1128/JCM.44.3.1178-1180.2006

Lifson AR; Rhame FS; Belloso WH; Dragsted UB; El-Sadr WM; Gatell JM; Hoy JF; Krum EA; Nelson R; Pedersen C, 2006, 'Reporting and evaluaton of HIV-related clinical endpoints in two multicenter international clinical trials', HIV Clinical Trials, vol. 7, pp. 125 - 141, http://dx.doi.org/10.1310/7MER-XFA7-1762-E2WR

Pett SL; Wand H; Law MG; Arduino R; Lopez JC; Knysz B; Pereira LC; Pollack S; Reiss P; Tambussi G, 2006, 'Evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial (ESPRIT): Geographical and gender differences in the baseline characteristics of participants', HIV Clinical Trials, vol. 7, pp. 70 - 85, http://dx.doi.org/10.1310/4733-ACQF-F3P4-2QAC

Samaras K; Pett S; Gowers A; McMurchie M; Cooper DA, 2005, 'Iatrogenic Cushing's Syndrome with Osteoporosis and Secondary Adrenal Failure in Human Immunodeficiency Virus-Infected Patients Receiving Inhaled Corticosteroids and Ritonavir-Boosted Protease Inhibit', Journal of Clinical Endocrinology and Metabolism, vol. 90, pp. 4394 - 4398, http://dx.doi.org/10.1210/jc.2005-0036

Pett SL; Williams LA; Day RO; Lloyd AR; Carr AD; Clezy KR; Emery S; Kaplan E; McPhee DA; McLachlan AJ, 2004, 'A phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, ^PEHRG214, in HIV-1-infected individuals', HIV Clinical Trials, vol. 5, pp. 91 - 98, http://dx.doi.org/10.1310/1FLN-8KFC-5HEQ-K19J

Pett SL; Kelleher A, 2004, 'Antiretroviral therapy-induced immune restoration in HIV infection: A double-edged sword?', Expert Review of Anti-Infective Therapy, vol. 2, pp. 335 - 339, http://dx.doi.org/10.1586/14787210.2.3.335

Pett SL; Kelleher AD, 2003, 'Cytokine therapies in HIV-1 infection: Present and future', Expert Review of Anti-Infective Therapy, vol. 1, pp. 83 - 96, http://dx.doi.org/10.1586/14787210.1.1.83

O Loughlin AJ; Pett SL; Anderson D; Yorke J; Chua R; Williams DB; Hayward CS; Keogh AM; Macdonald PS; Cunningham PH, 2003, 'Cytomegalovirus polymerase chain reaction tests can replace endoscopy and biopsy for the initial diagnosis of cytomegalovrius gastrointestinal disease in patients following heart transplantation', CSANZ

Pett SL; Kelleher AD, 2003, 'Cytokine therapies in HIV-1 infection: present and future', Expert Review of Anti-Infective Therapy, vol. 1, pp. 89 - 102

Pett SL; Dore GJ; Fielden RJ; Cooper DA, 2002, 'Cyclical hepatitis and early liver cirrhosis after hepatitis C seroconversion during pulsed antiretroviral therapy for primary HIV-1 [6]', AIDS, vol. 16, pp. 2364 - 2365, http://dx.doi.org/10.1097/00002030-200211220-00029

Pett SL; Emery S, 2001, 'Immunomodulators as adjunctive therapy for HIV-1 infection', Journal of Clinical Virology, vol. 22, pp. 289 - 295, http://dx.doi.org/10.1016/S1386-6532(01)00201-3

Suzuki K; Cunningham P; Harris C; Leas L; Zaunders J; Cooper DA; Kaufmann GR; Pett SL; Kelleher A; Mukaide M, 2001, 'Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine', AIDS Research and Human Retroviruses, vol. 17, pp. 1293 - 1296, http://dx.doi.org/10.1089/088922201750461366

Pett SL; Milliken S, 2000, 'Current review of the metabolic and endocrine disturbances in human immunodeficiency virus infection', Current Opinion in Endocrinology and Diabetes, vol. 7, pp. 96 - 101, http://dx.doi.org/10.1097/00060793-200004000-00009